Profile: Arbutus Biopharma Corp (ABUS.OQ)
ABUS.OQ on NASDAQ Stock Exchange Global Select Market
Change (% chg)
Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.
Arbutus Biopharma Corp
100-8900 Glenlyon Pky
BURNABY BC V5J 5J8